WO2008122789A3 - Methods for modulating lrrk2 - Google Patents
Methods for modulating lrrk2 Download PDFInfo
- Publication number
- WO2008122789A3 WO2008122789A3 PCT/GB2008/001211 GB2008001211W WO2008122789A3 WO 2008122789 A3 WO2008122789 A3 WO 2008122789A3 GB 2008001211 W GB2008001211 W GB 2008001211W WO 2008122789 A3 WO2008122789 A3 WO 2008122789A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lrrk2
- compound
- protein kinase
- kinase activity
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Psychology (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08718997A EP2132326B1 (en) | 2007-04-05 | 2008-04-07 | Methods |
CN200880017563A CN101688234A (en) | 2007-04-05 | 2008-04-07 | Methods for modulating lrrk2 |
CA2718580A CA2718580A1 (en) | 2007-04-05 | 2008-04-07 | Methods for identifying kinase modulators |
DK08718997.3T DK2132326T3 (en) | 2007-04-05 | 2008-04-07 | APPROACHES |
JP2010501595A JP2010523101A (en) | 2007-04-05 | 2008-04-07 | Adjustment method of LRRK2 |
US12/244,715 US7947468B2 (en) | 2007-04-05 | 2008-10-02 | Methods |
US12/553,932 US8206942B2 (en) | 2007-04-05 | 2009-09-03 | Methods of identifying LRRK2 inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91024207P | 2007-04-05 | 2007-04-05 | |
GB0706709.3 | 2007-04-05 | ||
US60/910,242 | 2007-04-05 | ||
GBGB0706709.3A GB0706709D0 (en) | 2007-04-05 | 2007-04-05 | Methods |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/244,715 Continuation-In-Part US7947468B2 (en) | 2007-04-05 | 2008-10-02 | Methods |
PCT/GB2009/002047 Continuation-In-Part WO2010031988A2 (en) | 2007-04-05 | 2009-08-24 | Methods |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008122789A2 WO2008122789A2 (en) | 2008-10-16 |
WO2008122789A3 true WO2008122789A3 (en) | 2008-12-04 |
Family
ID=38090954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2008/001211 WO2008122789A2 (en) | 2007-04-05 | 2008-04-07 | Methods for modulating lrrk2 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7947468B2 (en) |
EP (1) | EP2132326B1 (en) |
JP (1) | JP2010523101A (en) |
CN (1) | CN101688234A (en) |
CA (1) | CA2718580A1 (en) |
DK (1) | DK2132326T3 (en) |
GB (1) | GB0706709D0 (en) |
WO (1) | WO2008122789A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9156845B2 (en) | 2012-06-29 | 2015-10-13 | Pfizer Inc. | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors |
CN108709997B (en) * | 2018-05-28 | 2020-09-18 | 中国林业科学研究院林业研究所 | Substrate search method for LRR receptor kinase |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0706709D0 (en) | 2007-04-05 | 2007-05-16 | Medical Res Council | Methods |
US8206942B2 (en) | 2007-04-05 | 2012-06-26 | Medical Research Council | Methods of identifying LRRK2 inhibitors |
GB2463656B (en) * | 2008-09-18 | 2010-10-13 | Medical Res Council | Substrate of LRRK2 and methods of assessing LRRK2 activity |
JP2012254937A (en) * | 2009-09-11 | 2012-12-27 | Kyushu Univ | New matrix peptide of rho-kinase |
WO2011036211A1 (en) * | 2009-09-23 | 2011-03-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Polypeptides and nucleic acids for treating erbb2-dependent cancers |
US8367349B2 (en) | 2010-04-19 | 2013-02-05 | Medical Research Council | Methods for identifying modulators of LRRK2 |
US9345765B2 (en) | 2010-10-08 | 2016-05-24 | Shanghai Kexin Biotech Co., Ltd. | Diagnostic and therapeutic uses of moesin fragments |
JP6080763B2 (en) * | 2010-10-08 | 2017-02-15 | シャンハイ クーシン バイオテック カンパニー,リミテッド | Moesin modulator and use thereof |
CA2814023C (en) * | 2010-10-08 | 2018-01-16 | Shanghai Kexin Biotech Co., Ltd. | Moesin fragments and uses thereof |
WO2012045279A1 (en) * | 2010-10-08 | 2012-04-12 | Shanghai Kexin Biotech Co., Ltd. | Moesin fragments associated with immune thrombocytopenia |
CA2814026C (en) * | 2010-10-08 | 2017-07-11 | Shanghai Kexin Biotech Co., Ltd. | Moesin fragments associated with aplastic anemia |
BR112013013457A2 (en) * | 2010-11-30 | 2017-07-11 | Genentech Inc | methods for identifying a patient or subject, for predicting a subject's sensitivity, for identifying subjects who have parkinson's disease, and for determining the subject's response to therapy and assay for selecting compounds and compositions |
CA2933767C (en) | 2013-12-17 | 2018-11-06 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
WO2015176010A1 (en) | 2014-05-15 | 2015-11-19 | The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
AU2016322813B2 (en) | 2015-09-14 | 2021-04-01 | Pfizer Inc. | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors |
US20180179594A1 (en) * | 2016-10-31 | 2018-06-28 | Parkinson's Institute | Multiple system atrophy and the treatment thereof |
CN112843067B (en) * | 2019-11-26 | 2023-01-06 | 兰州大学 | Human LRRK2 protein small-molecule inhibitor and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030166222A1 (en) * | 2002-01-02 | 2003-09-04 | Millennium Pharmaceuticals, Inc. | 39267, human kinase family members and uses therefor |
WO2004074485A1 (en) * | 2003-02-24 | 2004-09-02 | Research Association For Biotechnology | Novel proteins and dnas encoding the same |
US20040265849A1 (en) * | 2002-11-22 | 2004-12-30 | Applera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007224411B2 (en) | 2006-03-14 | 2012-11-01 | Cellzome Gmbh | Methods for the identification of LRRK2 interacting molecules and for the purification of LRRK2 |
WO2008091799A2 (en) | 2007-01-22 | 2008-07-31 | The Trustees Of Columbia University In The City Of New York | Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants |
GB0706709D0 (en) | 2007-04-05 | 2007-05-16 | Medical Res Council | Methods |
-
2007
- 2007-04-05 GB GBGB0706709.3A patent/GB0706709D0/en not_active Ceased
-
2008
- 2008-04-07 JP JP2010501595A patent/JP2010523101A/en active Pending
- 2008-04-07 DK DK08718997.3T patent/DK2132326T3/en active
- 2008-04-07 EP EP08718997A patent/EP2132326B1/en not_active Not-in-force
- 2008-04-07 CN CN200880017563A patent/CN101688234A/en active Pending
- 2008-04-07 WO PCT/GB2008/001211 patent/WO2008122789A2/en active Application Filing
- 2008-04-07 CA CA2718580A patent/CA2718580A1/en not_active Abandoned
- 2008-10-02 US US12/244,715 patent/US7947468B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030166222A1 (en) * | 2002-01-02 | 2003-09-04 | Millennium Pharmaceuticals, Inc. | 39267, human kinase family members and uses therefor |
US20040265849A1 (en) * | 2002-11-22 | 2004-12-30 | Applera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
WO2004074485A1 (en) * | 2003-02-24 | 2004-09-02 | Research Association For Biotechnology | Novel proteins and dnas encoding the same |
Non-Patent Citations (5)
Title |
---|
DATABASE UniProt [online] 11 October 2005 (2005-10-11), "SubName: Full=Putative uncharacterized protein; Flags: Fragment;", XP002494863, retrieved from EBI accession no. UNIPROT:Q3UF33 Database accession no. Q3UF33 * |
JALEEL MAHABOOBI ET AL: "LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity", BIOCHEMICAL JOURNAL, vol. 405, no. Part 2, July 2007 (2007-07-01), pages 307 - 317, XP002494862, ISSN: 0264-6021(print) 1470-8728(ele * |
KATAYAMA S ET AL: "Antisense transcription in the mammalian transcriptome", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, WASHINGTON, DC, vol. 309, no. 5740, 2 September 2005 (2005-09-02), pages 1564 - 1566, XP003020135, ISSN: 0036-8075 * |
MATA ET AL: "LRRK2 in Parkinson's disease: protein domains and functional insights", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 5, 1 May 2006 (2006-05-01), pages 286 - 293, XP005415125, ISSN: 0166-2236 * |
MATSUI T ET AL: "RHO-KINASE PHOSPHORYLATES COOH-TERMINAL THREONINES OF EZRIN/RADIXIN/MOESIN (ERM) PROTEINS AND REGULATES THEIR HEAD-TO-TAIL ASSOCIATION", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 140, no. 3, 9 February 1998 (1998-02-09), pages 647 - 657, XP001083757, ISSN: 0021-9525 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9156845B2 (en) | 2012-06-29 | 2015-10-13 | Pfizer Inc. | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors |
CN108709997B (en) * | 2018-05-28 | 2020-09-18 | 中国林业科学研究院林业研究所 | Substrate search method for LRR receptor kinase |
Also Published As
Publication number | Publication date |
---|---|
JP2010523101A (en) | 2010-07-15 |
EP2132326A2 (en) | 2009-12-16 |
GB0706709D0 (en) | 2007-05-16 |
US20090142784A1 (en) | 2009-06-04 |
US7947468B2 (en) | 2011-05-24 |
CA2718580A1 (en) | 2008-10-16 |
WO2008122789A2 (en) | 2008-10-16 |
DK2132326T3 (en) | 2012-12-17 |
EP2132326B1 (en) | 2012-10-31 |
CN101688234A (en) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008122789A3 (en) | Methods for modulating lrrk2 | |
WO2008118148A3 (en) | Adiponectin for the treatment and diagnosis of albuminuria | |
WO2005109001A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
WO2009114603A3 (en) | Diffusion tensor imaging confidence analysis | |
WO2008005469A3 (en) | Igfbp2 biomarker | |
WO2008070137A3 (en) | Interferon alpha-induced pharmacodynamic markers | |
WO2008121742A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2006086561A3 (en) | Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus | |
WO2005089310A3 (en) | Breath test for oral malodor | |
WO2010031988A3 (en) | Polypeptides substrates of lrrk2 and uses thereof | |
WO2005119262A3 (en) | Methods, compositions and compound assays for inhibiting amyloid-beta protein production | |
WO2009108706A3 (en) | Methods for inhibiting six 1 and eya proteins | |
JP2008537481A5 (en) | ||
WO2015048804A3 (en) | Protein biomarker and uses thereof | |
WO2007104314A3 (en) | INHIBITION OF GASCl | |
WO2004029622A3 (en) | Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases | |
WO2010028313A3 (en) | Phosphoprotein analysis of carcinomas for assessment of drug sensitivity | |
WO2008147206A3 (en) | Means and methods for classifying samples of multiple sclerosis patients | |
EP1801232A4 (en) | Method of screening transmembrane enzyme inhibitory substance | |
WO2010035259A3 (en) | Compositions comprising soluble cd84 or anti-cd84 antibodies and methods for diagnosing and treating b-cll | |
Rubio et al. | Epigenetic control of somatostatin and cortistatin expression by β amyloid peptide | |
WO2008009854A3 (en) | Modulators of the abcd3 transporter in the treatment of acne or of hyperseborrhoea | |
WO2003059943A3 (en) | Conformation-specific, protein kinase binding peptides and related methods and products | |
WO2013033366A3 (en) | Methods and compositions for promoting glucose homeostasis | |
EP1363528A4 (en) | Methods for diagnosing and treating heart disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880017563.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08718997 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2010501595 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008718997 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2718580 Country of ref document: CA |